Adventrx Pharmaceuticals kommt hier der TURNAROUND ??? - 500 Beiträge pro Seite

[Wohnwunsch]

Sie Aktie befindet sich fast auf ihrem 52 Wochentief, sehen wir hier bald den Turnaround ?

[Wohnwunsch]

 
About ADVENTRX Pharmaceuticals, Inc.:

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens.

 

ADVENTRX Product Candidates:

 

ADVENTRX is currently focused on commercializing two late-stage product candidates in the U.S., ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), which are novel emulsion formulations of currently marketed chemotherapy drugs. The Company believes ANX-530 and ANX-514 may improve the safety of and have greater commercial potential than the currently marketed reference products, Navelbine and Taxotere, respectively, by:
 

Improving their safety and reducing the incidence and severity of adverse effects; and
Increasing their pharmacoeconomics and convenience to healthcare practitioners and patients.

Reformulating existing pharmaceutical products is an increasingly common product lifecycle-management technique. Between 2002 and 2005, nearly 40% of the products launched by the top 50 pharmaceutical manufacturers were reformulations. Finding new markets for and ways to modify and improve existing products is often an essential element of pharmaceutical companies' efforts to maintain or grow revenues in the face of patent expirations and competitive pressures.

Navelbine and Taxotere are intravenously-injected chemotherapy drugs commonly used to treat solid tumors. We believe the current formulations of these drugs have limitations that present opportunities for improvement. We are developing novel ways to formulate the active ingredient underlying each of these drugs that we believe may improve their safety profiles without adversely affecting efficacy. In addition, we believe our formulations may provide benefits to patients and practitioners that do not manifest themselves in traditional measures of safety or efficacy.

 

                                                                                                                            Collaborating to Advance Our Programs and Technologies

At AVI BioPharma we are committed to rapidly advancing our leading RNA-based technology platforms and pipeline. Strategically, we seek to build a diversified research and development portfolio balanced between select programs partnered with larger biopharmaceutical companies and AVI retained programs.

Platform Opportunities
Our RNA-based technologies and PMO-X, PMOplusplus™ and PPMO chemistries combine to make a versatile, collaboration-ready, therapeutics research and development platform with broad applicability. Our platform has demonstrated utility across multiple therapeutic categories, including the promise of potentially transformative, safe and effective treatment options for rare and infectious diseases.

Program Opportunities
In addition to offering our collaboration-ready RNA-based technology platform, we have multiple program opportunities available for partnering, including our clinical stage Duchenne muscular dystrophy program and several anti-infective and rare disease programs.

Beyond strategic partnerships with industry, AVI also maintains a continuing interest in establishing research-advancing collaborative agreements with select academic, governmental and non-governmental organizations.

For further information on partnering and collaboration with AVI, please contact Paul Medeiros, Chief Business Officer.

This page was last updated on July 22, 2010.

 

Some Helpful DD:                                                    

 http://www.avibio.com/

http://www.google.com/finance?q=AMEX:ANX

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-sec

ANX All in one.. >>  http://www.finviz.com/quote.ashx?t=anx&ty=c&ta=0&p=w

 

{C}{C}
ADVENTRX Reports Second Quarter 2010 Financial Results:

 
 SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the three and six months ended June 30, 2010.
"As we approach the midpoint of the third quarter, we remain focused on submitting a New Drug Application for Exelbine and reaffirm our intention to submit the Exelbine NDA in the fourth quarter of this year," said Brian M. Culley, ADVENTRX's Chief Executive Officer.  

"We are also exploring an expansion of our product pipeline and have found that, as a result of the difficult financing environment, many programs with substantial potential are available at attractive valuations," Mr. Culley continued.  "We believe our strong balance sheet, reflecting over $30 million in cash at June 30, will provide us with substantial leverage in any acquisition or merger discussions."

Second Quarter Financial Results

ADVENTRX's net loss applicable to common stock for the second quarter of 2010 was $5.0 million, or $0.39 per share, compared to net loss applicable to common stock of $3.8 million, or $1.02 per share, for the same period in 2009. Included in net loss applicable to common stock for the three months ended June 30, 2010 and 2009 were non-cash, deemed dividend expenses of $3.1 million and $1.2 million, respectively, related to the Company's May 2010 and June 2009 registered direct equity financings.

Research and development (R&D) expenses for the second quarter of 2010 were $0.6 million, a decrease of $0.8 million, or 56%, compared to $1.5 million for the same period in 2009. The decrease was due primarily to a $0.8 million decrease in external nonclinical study fees and expenses, attributable to a $1.0 million decrease in research-related manufacturing expenses for Exelbine and ANX-514, offset by a $0.2 million increase in fees for consulting services related to Exelbine and ANX-514.  

Selling, general and administrative (SG&A) expenses for the second quarter of 2010 were $1.3 million, an increase of $0.2 million, or 22%, compared to $1.1 million for the same period in 2009.  SG&A expenses for the three months ended June 30, 2009 were lower due primarily to a $0.2 million non-cash credit recorded in that period, which adjustment was made to correct an over-accrual of severance-related expenses in prior periods. Excluding the severance-related expenses adjustment, SG&A expenses for the three months ended June 30, 2010 and 2009 were comparable.

Year-to-Date Financial Results

ADVENTRX's net loss applicable to common stock for the six months ended June 30, 2010 was $10.0 million, or $0.86 per share, compared to net loss applicable to common stock of $7.0 million, or $1.90 per share, for the same period in 2009. Included in net loss applicable to common stock for the six months ended June 30, 2010 and 2009 were non-cash, deemed dividend expenses of approximately $5.6 million and $1.2 million, respectively, related to the Company's January and May 2010 and June 2009 registered direct equity financings.  

R&D expenses for the first half of 2010 were $1.9 million, a decrease of $1.2 million, or 40%, compared to $3.1 million for the same period in 2009.  The decrease was due primarily to a $0.7 million decrease in personnel costs attributable to lower headcount and the absence of severance costs in 2010 and a $0.5 million decrease in external bioequivalence trial expenses.

SG&A expenses for the first half of 2010 were $2.5 million, a decrease of $0.4 million, or 13%, compared to $2.9 million for the same period in 2009.  The decrease was due primarily to a $0.5 million decrease in personnel costs attributable to lower headcount and the absence of severance costs in 2010, a $0.2 million decrease in fees for professional legal, audit and tax services and a $0.1 million decrease in the cost of the Company's facilities lease, offset by a $0.3 million increase in director compensation and stock compensation expense and a $0.1 million increase in fees for accounting, investor relations and commercialization consulting services.  

Balance Sheet Highlights

As of June 30, 2010, the Company had cash of $31.2 million and stockholders' equity of $30.5 million.

Reverse Stock Split

All share and per-share information in this press release reflect the 1-for-25 reverse split of the Company's outstanding common stock that took place on April 23, 2010 at 4:01 p.m. Eastern time. All share and per-share information related to dates or periods prior to April 23, 2010 have been restated to reflect retrospective application of the reverse stock split.

 

ADVENTRX Announces 12-Month Stability Data Results for ANX-530

 
 
SAN DIEGO, Sept. 14 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site.  The 12-month stability data are consistent with the stability data collected at 6 and 9 months and will support the Company's submission of a New Drug Application (NDA) for Exelbine, which the Company expects to take place in the fourth quarter of this year.

 

 Investor FAQ :
 

1. When was the Company formed?
2. Where are the Company's offices located?
3. Where do the Company's shares trade?
4. Who is the Company's stock transfer agent?
5. What is the CUSIP number for the Company's common stock?
6. Does the Company issue dividends?
7. Does the Company offer a direct stock purchase program?
8. What is the Company's fiscal year end?
9. Who are the Company's independent auditors?
10. How can I receive ADVENTRX Pharmaceuticals' updates?
 

 
                                                                                             Stock Information

                                                                                                     Symbol: AMEX: ANX

                                                                                                                                 Shares Outstanding: ~ 15.5M as of 07-17-10

                                                                                                                                                     Float: TBA
                                                                        

 

                                                        

 

 

                                                                                                 

                                                                                                                                                         Chart ANX Real Time..

We watch, We Wait & We Learn.
Do Your Own due diligence.
Only you can decide when to Buy, Sell or Hold.

This message board is not affiliated with any company or organization.
No endorsement of or by any company or organization is implied by the posts on this board.
You are responsible for your own decisions and research before investing.

To Bookmark this Page, click Add To Favorites.   © 2010. I-box last update 5 Aug 2010. 
 

[Wohnwunsch]

http://stockcharts.com/c-sc/sc?chart=anx,uu%5Be,a%5Ddhclyiay…

[Wohnwunsch]

Adventrx Pharmaceuticals (ANX), a biopharmaceutical company, focuses on developing proprietary product candidates. This stock is trading up 4.6% at 60 cents per share in recent trading.

Today’s Range: $0.58-$0.63

52-Week Range: $0.45-$3.91

Volume: 1.1 million

Three-Month Average Volume: 286,871

Shares of ANX are moving sharply higher today after Vista Partners updated its coverage on the stock, and maintains its 12-month price target of $3.50 a share.

>>5 Stocks Under $10 Set to Soar

From a technical perspective, ANX is jumping higher here with monster volume, and this stock has started to flirt with breakout territory above some near-term overhead resistance at 61 cents.

Traders should now look for long-biased trades if ANX can manage to take out its 200-day moving average of 67 cents with high volume. Look for a sustained move or close above 67 cents with volume that’s near or above 286,871 shares. If we get that action soon, a much bigger breakout will trigger once ANX takes out more past resistance at 69 to 72 cents with volume. Any high-volume move over those levels will set this stock up to trend back towards $1 to $1.16 in the near future. It’s very possible ANX could hit $1.40 if it triggers high-volume moves over 72 cents and then $1.16.

[Wohnwunsch]

Antwort auf Beitrag Nr.: 43.387.327 von Wohnwunsch am 15.07.12 10:23:35

Hier konnte sich das Blatt schon sehr bald wenden, dieser Wert scheint noch eine
unentdeckte Perle zu sein.....

Es ist eben ein Biotech Wert, hier kann ständig die Bombe platzen, ich bleib hier dabei

[Wohnwunsch]

Antwort auf Beitrag Nr.: 43.387.331 von Wohnwunsch am 15.07.12 10:27:00

Hier sollte man wohl etwas Gedult mitbringen, der Knoten könnte aber
hier schnell platzen und die Aktie stark nach Norden laufen